Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and safety of ES16001 in patients with COVID-19
KCT0007426Phase 3Not yet recruiting
- Sponsor
- GENENCELL
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ES16001 in coronavirus disease 2019 (COVID-19), sponsored by GENENCELL. Planned start Apr 2022; status: not yet recruiting.
02
Drugs
ES16001
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on KCT0007426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0007426.